Sanofi to Acquire Blueprint Medicines for $9.1 Billion to Bolster Rare Immunology Portfolio

The deal carries a 27% premium and secures approved therapy Avapritinib plus early-stage immunology candidates under potentially $9.5 billion in milestone payments, preserving Sanofi’s 2025 outlook.